Avanos Medical (AVNS) Financials

$12.28 -0.05 (-0.41%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$12.28 +0.01 (+0.04%)

As of 05/2/2025 04:09 PM Eastern

Annual Income Statements for Avanos Medical

This table shows Avanos Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	51	-62	-392
Consolidated Net Income / (Loss)	51	-62	-392
Net Income / (Loss) Continuing Operations	22	-9.90	-386
Total Pre-Tax Income	27	-7.90	-403
Total Operating Income	36	4.20	-396
Total Gross Profit	394	380	381
Total Revenue	684	673	688
Operating Revenue	684	673	688
Total Cost of Revenue	290	294	307
Operating Cost of Revenue	290	294	307
Total Operating Expenses	359	376	778
Selling, General & Admin Expense	327	335	319
Research & Development Expense	29	27	26
Other Operating Expenses / (Income)	3.00	13	-3.90
Impairment Charge	0.00	0.00	437
Total Other Income / (Expense), net	-8.80	-12	-7.10
Interest Expense	10	15	12
Interest & Investment Income	1.20	2.90	5.10
Income Tax Expense	5.20	2.00	-17
Net Income / (Loss) Discontinued Operations	29	-52	-5.80
Basic Earnings per Share	$1.08	($1.32)	($8.53)
Weighted Average Basic Shares Outstanding	46.60M	46.20M	46.00M
Diluted Earnings per Share	$1.07	($1.32)	($8.53)
Weighted Average Diluted Shares Outstanding	46.60M	46.20M	46.00M
Weighted Average Basic & Diluted Shares Outstanding	46.60M	46.20M	46.00M

This table shows Avanos Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	16	17	-0.50	-68	-3.70	11	-0.90	1.80	4.30	-397
Consolidated Net Income / (Loss)	16	17	-0.50	-68	-3.70	11	-0.90	1.80	4.30	-397
Net Income / (Loss) Continuing Operations	11	0.30	-7.80	-4.30	-8.80	11	0.50	4.30	5.90	-397
Total Pre-Tax Income	10	1.70	-9.10	-5.10	-2.60	8.90	1.50	6.20	9.50	-421
Total Operating Income	13	4.00	-6.10	-2.10	1.20	11	4.00	6.30	12	-419
Total Gross Profit	100	86	91	98	96	95	95	96	93	98
Total Revenue	172	144	159	169	171	173	166	172	170	180
Operating Revenue	172	144	159	169	171	173	166	172	170	180
Total Cost of Revenue	72	58	68	72	76	78	71	76	78	82
Operating Cost of Revenue	72	58	68	72	76	78	71	76	78	82
Total Operating Expenses	87	82	98	100	94	84	91	89	81	517
Selling, General & Admin Expense	78	75	89	93	79	75	84	81	74	80
Research & Development Expense	7.10	6.70	7.50	6.80	6.10	6.80	7.00	6.30	7.20	5.70
Other Operating Expenses / (Income)	2.00	0.20	1.20	0.10	9.50	2.50	0.20	2.10	-0.60	-5.60
Total Other Income / (Expense), net	-2.70	-2.30	-3.00	-3.00	-3.80	-2.30	-2.50	-0.10	-2.50	-2.00
Interest Expense	3.00	3.00	3.50	3.50	4.70	3.30	3.10	3.10	3.20	2.80
Interest & Investment Income	0.30	0.70	0.50	0.50	0.90	1.00	0.60	3.00	0.70	0.80
Income Tax Expense	-0.90	1.40	-1.30	-0.80	6.20	-2.10	1.00	1.90	3.60	-24
Net Income / (Loss) Discontinued Operations	4.70	-	7.30	-64	5.10	-0.50	-1.40	-2.50	-1.60	-0.30
Basic Earnings per Share	$0.34	$0.36	($0.01)	($1.46)	($0.08)	$0.23	($0.02)	$0.04	$0.10	($8.65)
Weighted Average Basic Shares Outstanding	46.50M	46.60M	46.67M	46.87M	46.43M	46.20M	45.90M	45.95M	45.96M	46.00M
Diluted Earnings per Share	$0.33	$0.37	($0.01)	($1.46)	($0.08)	$0.23	($0.02)	$0.04	$0.09	($8.64)
Weighted Average Diluted Shares Outstanding	46.50M	46.60M	46.67M	46.87M	46.43M	46.20M	45.90M	45.95M	45.96M	46.00M
Weighted Average Basic & Diluted Shares Outstanding	46.50M	46.60M	46.67M	46.87M	46.43M	46.20M	45.90M	45.95M	45.96M	46.00M

This table details how cash moves in and out of Avanos Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	9.20	-40	20
Net Cash From Operating Activities	91	32	101
Net Cash From Continuing Operating Activities	91	32	101
Net Income / (Loss) Continuing Operations	51	-62	-392
Consolidated Net Income / (Loss)	51	-62	-392
Depreciation Expense	48	46	46
Non-Cash Adjustments To Reconcile Net Income	17	89	452
Changes in Operating Assets and Liabilities, net	-24	-40	-4.40
Net Cash From Investing Activities	-135	22	-28
Net Cash From Continuing Investing Activities	-135	22	-28
Purchase of Property, Plant & Equipment	-19	-18	-18
Acquisitions	-116	-50	0.00
Divestitures	0.00	89	2.10
Other Investing Activities, net	0.00	-	-12
Net Cash From Financing Activities	57	-94	-49
Net Cash From Continuing Financing Activities	57	-94	-49
Repayment of Debt	-300	-120	-54
Repurchase of Common Equity	-46	-19	-13
Issuance of Debt	400	55	20
Other Financing Activities, net	1.70	-10	-2.70
Effect of Exchange Rate Changes	-3.00	-	-4.10
Cash Interest Paid	8.10	15	12
Cash Income Taxes Paid	2.90	-24	-3.30

This table details how cash moves in and out of Avanos Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	11	11	-32	-14	25	-19	-12	16	-3.20	19
Net Cash From Operating Activities	28	34	-6.80	-2.60	29	13	-8.00	28	23	58
Net Cash From Continuing Operating Activities	28	34	-6.80	-2.60	29	13	-8.00	28	23	58
Net Income / (Loss) Continuing Operations	16	17	-0.50	-68	-3.70	11	-0.90	1.80	4.30	-397
Consolidated Net Income / (Loss)	16	17	-0.50	-68	-3.70	11	-0.90	1.80	4.30	-397
Depreciation Expense	12	13	12	12	11	12	11	11	12	11
Non-Cash Adjustments To Reconcile Net Income	4.10	5.10	4.00	63	5.00	17	3.90	3.80	2.70	441
Changes in Operating Assets and Liabilities, net	-3.00	-1.70	-22	-9.00	17	-26	-22	11	4.30	2.80
Net Cash From Investing Activities	-4.70	-4.90	-4.00	-6.50	-49	81	-2.00	-5.90	-12	-7.60
Net Cash From Continuing Investing Activities	-4.70	-4.90	-4.00	-6.50	-49	81	-2.00	-5.90	-12	-7.60
Purchase of Property, Plant & Equipment	-5.30	-4.90	-4.00	-4.00	-3.90	-5.90	-4.10	-5.90	-3.00	-4.80
Other Investing Activities, net	-	-	-	-	-	-	-	-	-	-2.80
Net Cash From Financing Activities	-10	-22	-22	-4.10	47	-115	-0.70	-5.00	-16	-27
Net Cash From Continuing Financing Activities	-10	-22	-22	-4.10	47	-115	-0.70	-5.00	-16	-27
Repayment of Debt	-	-22	-22	-1.50	-	-97	-12	-1.50	-13	-27
Repurchase of Common Equity	-11	-0.40	-1.10	-2.60	-9.20	-6.20	-9.10	-3.50	-0.10	-0.10
Effect of Exchange Rate Changes	-3.00	3.80	-	-	-1.60	-	-	-	1.80	-4.20

This table presents Avanos Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	1,787	1,692	1,154
Total Current Assets	624	487	393
Cash & Equivalents	128	88	108
Accounts Receivable	168	143	133
Inventories, net	132	163	139
Prepaid Expenses	14	29	14
Other Current Nonoperating Assets	182	65	0.00
Plant, Property, & Equipment, net	119	117	111
Total Noncurrent Assets	1,044	1,088	650
Goodwill	760	796	456
Intangible Assets	234	240	112
Noncurrent Deferred & Refundable Income Taxes	4.60	6.50	25
Other Noncurrent Operating Assets	45	46	57
Total Liabilities & Shareholders' Equity	1,787	1,692	1,154
Total Liabilities	496	456	326
Total Current Liabilities	191	235	166
Short-Term Debt	6.20	8.60	9.40
Accounts Payable	68	56	54
Accrued Expenses	98	93	91
Other Current Liabilities	12	13	11
Other Current Nonoperating Liabilities	7.10	64	0.00
Total Noncurrent Liabilities	305	222	160
Long-Term Debt	226	159	125
Noncurrent Deferred & Payable Income Tax Liabilities	25	24	5.50
Other Noncurrent Operating Liabilities	53	38	29
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,291	1,236	829
Total Preferred & Common Equity	1,291	1,236	829
Preferred Stock	0.00	0.00	0.00
Total Common Equity	1,291	1,236	829
Common Stock	1,647	1,664	1,679
Retained Earnings	-253	-315	-707
Accumulated Other Comprehensive Income / (Loss)	-36	-27	-45
Other Equity Adjustments	-67	-86	-99

This table presents Avanos Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	1,775	1,735	1,667	1,725	1,661	1,658	1,656
Total Current Assets	470	454	507	525	468	474	473
Cash & Equivalents	117	96	82	107	76	92	89
Accounts Receivable	146	143	152	145	131	123	132
Inventories, net	194	200	148	157	166	164	162
Prepaid Expenses	13	15	16	14	29	22	16
Other Current Nonoperating Assets	-	-	109	102	67	73	74
Plant, Property, & Equipment, net	163	164	123	117	116	111	110
Total Noncurrent Assets	1,142	1,118	1,037	1,084	1,077	1,073	1,074
Goodwill	824	822	763	792	795	794	795
Intangible Assets	259	245	223	242	233	226	220
Noncurrent Deferred & Refundable Income Taxes	11	4.50	4.40	4.30	6.30	6.30	6.60
Other Noncurrent Operating Assets	49	47	48	46	43	46	52
Total Liabilities & Shareholders' Equity	1,775	1,735	1,667	1,725	1,661	1,658	1,656
Total Liabilities	512	436	432	503	433	436	427
Total Current Liabilities	162	159	161	171	205	208	213
Short-Term Debt	6.20	6.20	6.20	6.20	9.40	10	9.40
Accounts Payable	63	60	65	52	57	51	54
Accrued Expenses	80	81	73	97	75	80	83
Other Current Liabilities	13	12	14	13	12	14	14
Other Current Nonoperating Liabilities	-	-	2.70	2.50	52	53	53
Total Noncurrent Liabilities	349	278	271	332	228	228	214
Long-Term Debt	248	205	203	258	167	165	153
Noncurrent Deferred & Payable Income Tax Liabilities	37	25	22	29	24	23	24
Other Noncurrent Operating Liabilities	65	48	46	45	37	39	37
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,264	1,299	1,235	1,222	1,228	1,222	1,230
Total Preferred & Common Equity	1,264	1,299	1,235	1,222	1,228	1,222	1,230
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,264	1,299	1,235	1,222	1,228	1,222	1,230
Common Stock	1,643	1,652	1,655	1,660	1,668	1,672	1,675
Retained Earnings	-270	-254	-322	-325	-316	-314	-310
Accumulated Other Comprehensive Income / (Loss)	-43	-31	-28	-33	-30	-38	-37
Other Equity Adjustments	-	-68	-71	-80	-95	-99	-99

This table displays calculated financial ratios and metrics derived from Avanos Medical's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	16.54%	-1.58%	2.15%
EBITDA Growth	11,985.71%	-39.54%	-797.22%
EBIT Growth	191.03%	-88.17%	-9,533.33%
NOPAT Growth	204.71%	-89.72%	-9,533.33%
Net Income Growth	701.59%	-222.38%	-534.47%
EPS Growth	723.08%	-223.36%	-546.21%
Operating Cash Flow Growth	4.12%	-64.36%	210.80%
Free Cash Flow Firm Growth	476.19%	-202.42%	298.74%
Invested Capital Growth	-4.78%	7.78%	-34.98%
Revenue Q/Q Growth	18.68%	4.63%	0.92%
EBITDA Q/Q Growth	58.17%	11.78%	-541.69%
EBIT Q/Q Growth	303.41%	240.00%	-1,282.69%
NOPAT Q/Q Growth	210.58%	240.00%	-1,095.75%
Net Income Q/Q Growth	12.47%	-11.55%	-2,597.45%
EPS Q/Q Growth	13.83%	-11.86%	-2,608.82%
Operating Cash Flow Q/Q Growth	-16.83%	-39.33%	81.44%
Free Cash Flow Firm Q/Q Growth	176.66%	-177.69%	602.27%
Invested Capital Q/Q Growth	-12.83%	2.80%	-33.25%
Profitability Metrics	-	-	-
Gross Margin	57.62%	56.39%	55.44%
EBITDA Margin	12.16%	7.47%	-50.99%
Operating Margin	5.19%	0.62%	-57.60%
EBIT Margin	5.19%	0.62%	-57.60%
Profit (Net Income) Margin	7.38%	-9.18%	-57.01%
Tax Burden Percent	189.14%	782.28%	97.22%
Interest Burden Percent	75.21%	-188.10%	101.79%
Effective Tax Rate	19.48%	0.00%	0.00%
Return on Invested Capital (ROIC)	2.28%	0.23%	-25.55%
ROIC Less NNEP Spread (ROIC-NNEP)	-72.13%	-1,422.63%	-241.06%
Return on Net Nonoperating Assets (RNNOA)	1.66%	-5.12%	-12.43%
Return on Equity (ROE)	3.94%	-4.89%	-37.98%
Cash Return on Invested Capital (CROIC)	7.18%	-7.26%	16.85%
Operating Return on Assets (OROA)	2.09%	0.24%	-27.84%
Return on Assets (ROA)	2.98%	-3.55%	-27.55%
Return on Common Equity (ROCE)	3.94%	-4.89%	-37.98%
Return on Equity Simple (ROE_SIMPLE)	3.91%	-5.00%	-47.33%
Net Operating Profit after Tax (NOPAT)	29	2.94	-277
NOPAT Margin	4.18%	0.44%	-40.32%
Net Nonoperating Expense Percent (NNEP)	74.41%	1,422.86%	215.51%
Return On Investment Capital (ROIC_SIMPLE)	1.88%	0.21%	-28.79%
Cost of Revenue to Revenue	42.38%	43.61%	44.56%
SG&A Expenses to Revenue	47.73%	49.75%	46.31%
R&D to Revenue	4.27%	4.04%	3.81%
Operating Expenses to Revenue	52.43%	55.77%	113.04%
Earnings before Interest and Taxes (EBIT)	36	4.20	-396
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	83	50	-351
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.97	0.84	0.88
Price to Tangible Book Value (P/TBV)	4.24	5.19	2.81
Price to Revenue (P/Rev)	1.84	1.55	1.06
Price to Earnings (P/E)	24.92	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	4.01%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.12	0.85	0.89
Enterprise Value to Revenue (EV/Rev)	1.99	1.67	1.10
Enterprise Value to EBITDA (EV/EBITDA)	16.38	22.30	0.00
Enterprise Value to EBIT (EV/EBIT)	38.40	267.05	0.00
Enterprise Value to NOPAT (EV/NOPAT)	47.68	381.51	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	14.99	34.62	7.53
Enterprise Value to Free Cash Flow (EV/FCFF)	15.16	0.00	4.15
Leverage & Solvency	-	-	-
Debt to Equity	0.18	0.14	0.16
Long-Term Debt to Equity	0.18	0.13	0.15
Financial Leverage	-0.02	0.00	0.05
Leverage Ratio	1.32	1.38	1.38
Compound Leverage Factor	1.00	-2.59	1.40
Debt to Total Capital	15.26%	11.96%	13.98%
Short-Term Debt to Total Capital	0.41%	0.61%	0.98%
Long-Term Debt to Total Capital	14.85%	11.35%	13.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.74%	88.04%	86.02%
Debt to EBITDA	2.79	3.34	-0.38
Net Debt to EBITDA	1.26	1.60	-0.08
Long-Term Debt to EBITDA	2.72	3.17	-0.36
Debt to NOPAT	8.13	57.14	-0.49
Net Debt to NOPAT	3.67	27.31	-0.10
Long-Term Debt to NOPAT	7.92	54.22	-0.45
Altman Z-Score	2.06	1.69	0.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.27	2.08	2.37
Quick Ratio	1.55	0.98	1.45
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	90	-92	183
Operating Cash Flow to CapEx	470.98%	182.02%	565.73%
Free Cash Flow to Firm to Interest Expense	8.99	-6.14	15.00
Operating Cash Flow to Interest Expense	9.09	2.16	8.25
Operating Cash Flow Less CapEx to Interest Expense	7.16	0.97	6.80
Efficiency Ratios	-	-	-
Asset Turnover	0.40	0.39	0.48
Accounts Receivable Turnover	4.57	4.33	4.99
Inventory Turnover	1.99	1.99	2.03
Fixed Asset Turnover	4.77	5.71	6.04
Accounts Payable Turnover	4.66	4.73	5.54
Days Sales Outstanding (DSO)	79.79	84.22	73.13
Days Inventory Outstanding (DIO)	183.57	183.68	179.82
Days Payable Outstanding (DPO)	78.25	77.20	65.85
Cash Conversion Cycle (CCC)	185.11	190.70	187.09
Capital & Investment Metrics	-	-	-
Invested Capital	1,221	1,316	856
Invested Capital Turnover	0.55	0.53	0.63
Increase / (Decrease) in Invested Capital	-61	95	-460
Enterprise Value (EV)	1,363	1,122	759
Market Capitalization	1,258	1,041	732
Book Value per Share	$27.77	$26.63	$18.03
Tangible Book Value per Share	$6.38	$4.32	$5.67
Total Capital	1,524	1,404	963
Total Debt	233	168	135
Total Long-Term Debt	226	159	125
Net Debt	105	80	27
Capital Expenditures (CapEx)	19	18	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	312	173	129
Debt-free Net Working Capital (DFNWC)	439	261	237
Net Working Capital (NWC)	433	252	228
Net Nonoperating Expense (NNE)	-22	65	115
Net Nonoperating Obligations (NNO)	-70	80	27
Total Depreciation and Amortization (D&A)	48	46	46
Debt-free, Cash-free Net Working Capital to Revenue	45.55%	25.74%	18.78%
Debt-free Net Working Capital to Revenue	64.22%	38.76%	34.44%
Net Working Capital to Revenue	63.31%	37.49%	33.08%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$1.08	($1.32)	($8.53)
Adjusted Weighted Average Basic Shares Outstanding	46.60M	46.20M	46.00M
Adjusted Diluted Earnings per Share	$1.07	($1.32)	($8.53)
Adjusted Weighted Average Diluted Shares Outstanding	46.60M	46.20M	46.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.60M	46.20M	46.00M
Normalized Net Operating Profit after Tax (NOPAT)	29	2.94	28
Normalized NOPAT Margin	4.18%	0.44%	4.12%
Pre Tax Income Margin	3.90%	-1.17%	-58.64%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	3.55	0.28	-32.48
NOPAT to Interest Expense	2.86	0.20	-22.73
EBIT Less CapEx to Interest Expense	1.62	-0.91	-33.93
NOPAT Less CapEx to Interest Expense	0.93	-0.99	-24.19
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	90.10%	-30.91%	-3.26%

This table displays calculated financial ratios and metrics derived from Avanos Medical's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-6.41%	300.84%	-19.30%	-0.88%	-0.58%	20.77%	4.27%	1.36%	-0.53%	3.64%
EBITDA Growth	87.69%	231.82%	-69.54%	-56.68%	-50.00%	30.46%	156.67%	87.23%	94.26%	-1,894.71%
EBIT Growth	276.47%	117.62%	-170.93%	-120.79%	-90.63%	180.00%	165.57%	400.00%	900.00%	-3,836.61%
NOPAT Growth	131.36%	104.44%	-167.12%	-123.04%	-93.97%	1,861.05%	131.23%	397.24%	787.22%	-2,216.28%
Net Income Growth	144.48%	49.56%	-109.26%	-644.80%	-123.57%	-37.87%	-80.00%	102.64%	216.22%	-3,883.81%
EPS Growth	145.21%	54.17%	-109.09%	-661.54%	-124.24%	-37.84%	-100.00%	102.74%	212.50%	-3,856.52%
Operating Cash Flow Growth	22.41%	-35.32%	-477.78%	-109.63%	2.46%	-62.31%	-17.65%	1,169.23%	-20.96%	355.91%
Free Cash Flow Firm Growth	-1,697.71%	129.57%	84.09%	550.59%	256.78%	-230.89%	971.51%	-117.03%	-95.35%	306.20%
Invested Capital Growth	6.98%	-4.78%	0.52%	-10.19%	-8.61%	7.78%	-7.04%	2.26%	0.14%	-34.98%
Revenue Q/Q Growth	0.82%	-16.72%	11.01%	6.34%	1.12%	1.17%	-4.15%	3.37%	-0.76%	5.40%
EBITDA Q/Q Growth	12.44%	-28.69%	-65.52%	56.67%	29.79%	86.07%	-32.16%	14.29%	34.66%	-1,818.99%
EBIT Q/Q Growth	26.73%	-68.75%	-252.50%	65.57%	157.14%	833.33%	-64.29%	57.50%	90.48%	-3,587.50%
NOPAT Q/Q Growth	118.54%	-94.94%	-704.92%	65.57%	157.14%	1,547.94%	-90.37%	227.70%	70.57%	-4,030.83%
Net Income Q/Q Growth	25.60%	7.64%	-102.96%	-13,520.00%	94.57%	383.78%	-108.57%	300.00%	138.89%	-9,339.53%
EPS Q/Q Growth	26.92%	12.12%	-102.70%	-14,500.00%	94.52%	387.50%	-108.70%	300.00%	125.00%	-9,700.00%
Operating Cash Flow Q/Q Growth	5.19%	18.66%	-120.18%	61.76%	1,219.23%	-56.36%	-162.99%	447.50%	-17.27%	151.74%
Free Cash Flow Firm Q/Q Growth	-147.31%	180.05%	-118.66%	1,319.79%	-13.95%	-166.83%	224.24%	-123.83%	123.52%	2,860.57%
Invested Capital Q/Q Growth	0.10%	-12.83%	15.82%	-11.13%	1.86%	2.80%	-0.11%	-2.24%	-0.25%	-33.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	58.15%	59.79%	57.38%	57.73%	55.75%	54.82%	57.07%	55.68%	54.52%	54.57%
EBITDA Margin	14.16%	12.13%	3.77%	5.55%	7.12%	13.10%	9.27%	10.25%	13.91%	-226.84%
Operating Margin	7.43%	2.79%	-3.83%	-1.24%	0.70%	6.46%	2.41%	3.67%	7.04%	-233.02%
EBIT Margin	7.43%	2.79%	-3.83%	-1.24%	0.70%	6.46%	2.41%	3.67%	7.04%	-233.02%
Profit (Net Income) Margin	9.11%	11.78%	-0.31%	-40.20%	-2.16%	6.06%	-0.54%	1.05%	2.52%	-221.21%
Tax Burden Percent	155.45%	994.12%	5.49%	1,335.29%	142.31%	117.98%	-60.00%	29.03%	45.26%	94.48%
Interest Burden Percent	78.91%	42.50%	149.18%	242.86%	-216.67%	79.46%	37.50%	98.41%	79.17%	100.48%
Effective Tax Rate	-8.91%	82.35%	0.00%	0.00%	0.00%	-23.60%	66.67%	30.65%	37.89%	0.00%
Return on Invested Capital (ROIC)	3.44%	0.27%	-1.23%	-0.42%	0.24%	4.24%	0.40%	1.37%	2.33%	-103.34%
ROIC Less NNEP Spread (ROIC-NNEP)	5.35%	-54.72%	1.61%	-79.18%	-4.43%	-69.23%	-1.81%	-4.71%	-3.42%	-299.30%
Return on Net Nonoperating Assets (RNNOA)	0.39%	1.26%	0.17%	-5.39%	-0.35%	-0.25%	-0.14%	-0.16%	-0.15%	-15.44%
Return on Equity (ROE)	3.83%	1.53%	-1.06%	-5.81%	-0.11%	3.99%	0.26%	1.20%	2.17%	-118.78%
Cash Return on Invested Capital (CROIC)	-8.65%	7.18%	0.67%	11.19%	8.84%	-7.26%	6.67%	-1.34%	2.03%	16.85%
Operating Return on Assets (OROA)	2.54%	1.12%	-1.41%	-0.47%	0.26%	2.50%	0.96%	1.51%	2.84%	-112.60%
Return on Assets (ROA)	3.11%	4.75%	-0.12%	-15.15%	-0.79%	2.35%	-0.22%	0.43%	1.02%	-106.90%
Return on Common Equity (ROCE)	3.83%	1.53%	-1.06%	-5.81%	-0.11%	3.99%	0.26%	1.20%	2.17%	-118.78%
Return on Equity Simple (ROE_SIMPLE)	3.55%	0.00%	3.43%	-2.92%	-4.53%	0.00%	-5.07%	0.63%	1.28%	0.00%
Net Operating Profit after Tax (NOPAT)	14	0.71	-4.27	-1.47	0.84	14	1.33	4.37	7.45	-293
NOPAT Margin	8.09%	0.49%	-2.68%	-0.87%	0.49%	7.99%	0.80%	2.54%	4.37%	-163.11%
Net Nonoperating Expense Percent (NNEP)	-1.91%	54.99%	-2.84%	78.76%	4.66%	73.47%	2.21%	6.07%	5.74%	195.96%
Return On Investment Capital (ROIC_SIMPLE)	-	0.05%	-	-	-	0.99%	-	-	-	-30.41%
Cost of Revenue to Revenue	41.85%	40.21%	42.62%	42.27%	44.25%	45.18%	42.93%	44.32%	45.48%	45.43%
SG&A Expenses to Revenue	45.44%	52.20%	55.74%	54.90%	45.94%	42.99%	50.33%	47.12%	43.60%	44.38%
R&D to Revenue	4.12%	4.67%	4.71%	4.01%	3.56%	3.92%	4.21%	3.67%	4.23%	3.17%
Operating Expenses to Revenue	50.73%	57.00%	61.21%	58.97%	55.05%	48.36%	54.67%	52.01%	47.48%	287.58%
Earnings before Interest and Taxes (EBIT)	13	4.00	-6.10	-2.10	1.20	11	4.00	6.30	12	-419
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	24	17	6.00	9.40	12	23	15	18	24	-407
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.80	0.97	1.07	0.97	0.78	0.84	0.75	0.75	0.90	0.88
Price to Tangible Book Value (P/TBV)	5.59	4.24	5.96	4.78	5.03	5.19	4.62	4.54	5.15	2.81
Price to Revenue (P/Rev)	1.76	1.84	2.15	1.85	1.47	1.55	1.36	1.34	1.62	1.06
Price to Earnings (P/E)	22.55	24.92	31.07	0.00	0.00	0.00	0.00	118.75	70.33	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.43%	4.01%	3.22%	0.00%	0.00%	0.00%	0.00%	0.84%	1.42%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.82	1.12	1.06	1.05	0.86	0.85	0.78	0.78	0.92	0.89
Enterprise Value to Revenue (EV/Rev)	1.99	1.99	2.32	2.05	1.72	1.67	1.51	1.46	1.73	1.10
Enterprise Value to EBITDA (EV/EBITDA)	21.85	16.38	21.60	23.09	24.56	22.30	17.17	14.69	14.83	0.00
Enterprise Value to EBIT (EV/EBIT)	130.62	38.40	72.17	153.55	0.00	267.05	71.69	43.93	35.14	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	47.68	89.56	219.35	0.00	381.51	0.00	87.87	42.26	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	10.52	14.99	18.24	25.06	20.70	34.62	32.86	16.19	21.21	7.53
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	15.16	158.65	8.89	9.33	0.00	11.26	0.00	45.18	4.15
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.20	0.18	0.16	0.17	0.22	0.14	0.14	0.14	0.13	0.16
Long-Term Debt to Equity	0.20	0.18	0.16	0.16	0.21	0.13	0.14	0.13	0.12	0.15
Financial Leverage	0.07	-0.02	0.10	0.07	0.08	0.00	0.08	0.03	0.04	0.05
Leverage Ratio	1.34	1.32	1.37	1.38	1.41	1.38	1.34	1.35	1.38	1.38
Compound Leverage Factor	1.05	0.56	2.04	3.34	-3.05	1.09	0.50	1.33	1.09	1.39
Debt to Total Capital	16.74%	15.26%	13.97%	14.51%	17.79%	11.96%	12.57%	12.53%	11.64%	13.98%
Short-Term Debt to Total Capital	0.41%	0.41%	0.41%	0.43%	0.42%	0.61%	0.67%	0.73%	0.68%	0.98%
Long-Term Debt to Total Capital	16.33%	14.85%	13.56%	14.08%	17.38%	11.35%	11.90%	11.80%	10.97%	13.01%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	83.26%	84.74%	86.03%	85.49%	82.21%	88.04%	87.43%	87.47%	88.36%	86.02%
Debt to EBITDA	4.83	2.79	3.03	3.66	5.88	3.34	2.96	2.58	2.04	-0.38
Net Debt to EBITDA	2.60	1.26	1.66	2.23	3.50	1.60	1.69	1.22	0.92	-0.08
Long-Term Debt to EBITDA	4.71	2.72	2.95	3.55	5.74	3.17	2.80	2.43	1.92	-0.36
Debt to NOPAT	-9.83	8.13	12.58	34.80	-125.95	57.14	-20.84	15.43	5.82	-0.49
Net Debt to NOPAT	-5.30	3.67	6.87	21.21	-74.95	27.31	-11.90	7.30	2.62	-0.10
Long-Term Debt to NOPAT	-9.59	7.92	12.21	33.77	-123.00	54.22	-19.73	14.53	5.48	-0.45
Altman Z-Score	1.53	2.01	2.27	2.02	1.49	1.71	1.62	1.61	1.92	0.13
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.90	3.27	2.86	3.16	3.07	2.08	2.28	2.28	2.22	2.37
Quick Ratio	1.62	1.55	1.50	1.46	1.48	0.98	1.01	1.03	1.04	1.45
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	62	-12	141	121	-81	101	-24	5.65	167
Operating Cash Flow to CapEx	535.85%	687.76%	-170.00%	-65.00%	746.15%	215.25%	-195.12%	471.19%	766.67%	1,206.25%
Free Cash Flow to Firm to Interest Expense	-25.82	20.67	-3.31	40.32	25.84	-24.59	32.53	-7.75	1.77	59.77
Operating Cash Flow to Interest Expense	9.47	11.23	-1.94	-0.74	6.19	3.85	-2.58	8.97	7.19	20.68
Operating Cash Flow Less CapEx to Interest Expense	7.70	9.60	-3.09	-1.89	5.36	2.06	-3.90	7.06	6.25	18.96
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.40	0.37	0.38	0.37	0.39	0.40	0.41	0.40	0.48
Accounts Receivable Turnover	4.37	4.57	4.25	4.33	4.42	4.33	4.96	4.96	4.92	4.99
Inventory Turnover	1.34	1.99	1.49	1.70	1.56	1.99	1.62	1.93	1.90	2.03
Fixed Asset Turnover	3.46	4.77	3.91	4.49	4.59	5.71	4.86	5.85	6.02	6.04
Accounts Payable Turnover	4.01	4.66	4.33	4.16	4.76	4.73	5.09	5.16	5.70	5.54
Days Sales Outstanding (DSO)	83.49	79.79	85.97	84.30	82.64	84.22	73.53	73.63	74.21	73.13
Days Inventory Outstanding (DIO)	272.20	183.57	244.43	215.03	234.11	183.68	224.65	188.98	191.71	179.82
Days Payable Outstanding (DPO)	90.94	78.25	84.35	87.83	76.74	77.20	71.65	70.70	63.98	65.85
Cash Conversion Cycle (CCC)	264.76	185.11	246.05	211.50	240.01	190.70	226.53	191.90	201.93	187.09
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,401	1,221	1,414	1,257	1,280	1,316	1,314	1,285	1,282	856
Invested Capital Turnover	0.43	0.55	0.46	0.49	0.48	0.53	0.50	0.54	0.53	0.63
Increase / (Decrease) in Invested Capital	91	-61	7.30	-143	-121	95	-100	28	1.80	-460
Enterprise Value (EV)	1,149	1,363	1,501	1,321	1,105	1,122	1,025	997	1,177	759
Market Capitalization	1,012	1,258	1,386	1,193	948	1,041	924	914	1,104	732
Book Value per Share	$27.18	$27.77	$27.87	$26.46	$26.07	$26.63	$26.75	$26.62	$26.76	$18.03
Tangible Book Value per Share	$3.90	$6.38	$4.99	$5.35	$4.02	$4.32	$4.36	$4.39	$4.67	$5.67
Total Capital	1,518	1,524	1,510	1,444	1,487	1,404	1,405	1,397	1,392	963
Total Debt	254	233	211	210	265	168	177	175	162	135
Total Long-Term Debt	248	226	205	203	258	159	167	165	153	125
Net Debt	137	105	115	128	157	80	101	83	73	27
Capital Expenditures (CapEx)	5.30	4.90	4.00	4.00	3.90	5.90	4.10	5.90	3.00	4.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)	197	312	206	271	253	173	196	184	180	129
Debt-free Net Working Capital (DFNWC)	314	439	302	353	360	261	272	276	269	237
Net Working Capital (NWC)	308	433	295	346	354	252	263	266	260	228
Net Nonoperating Expense (NNE)	-1.76	-16	-3.77	67	4.54	3.34	2.23	2.57	3.15	104
Net Nonoperating Obligations (NNO)	137	-70	115	22	58	80	87	63	52	27
Total Depreciation and Amortization (D&A)	12	13	12	12	11	12	11	11	12	11
Debt-free, Cash-free Net Working Capital to Revenue	34.16%	45.55%	31.86%	42.02%	39.32%	25.74%	28.85%	26.95%	26.43%	18.78%
Debt-free Net Working Capital to Revenue	54.46%	64.22%	46.67%	54.71%	55.96%	38.76%	39.99%	40.46%	39.49%	34.44%
Net Working Capital to Revenue	53.38%	63.31%	45.71%	53.75%	55.00%	37.49%	38.61%	38.97%	38.11%	33.08%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.34	$0.36	($0.01)	($1.46)	($0.08)	$0.23	($0.02)	$0.04	$0.10	($8.65)
Adjusted Weighted Average Basic Shares Outstanding	46.50M	46.60M	46.67M	46.87M	46.43M	46.20M	45.90M	45.95M	45.96M	46.00M
Adjusted Diluted Earnings per Share	$0.33	$0.37	($0.01)	($1.46)	($0.08)	$0.23	($0.02)	$0.04	$0.09	($8.64)
Adjusted Weighted Average Diluted Shares Outstanding	46.50M	46.60M	46.67M	46.87M	46.43M	46.20M	45.90M	45.95M	45.96M	46.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.50M	46.60M	46.67M	46.87M	46.43M	46.20M	45.90M	45.95M	45.96M	46.00M
Normalized Net Operating Profit after Tax (NOPAT)	8.96	2.80	-4.27	-1.47	0.84	7.84	2.80	4.37	7.45	-293
Normalized NOPAT Margin	5.20%	1.95%	-2.68%	-0.87%	0.49%	4.52%	1.69%	2.54%	4.37%	-163.11%
Pre Tax Income Margin	5.86%	1.18%	-5.71%	-3.01%	-1.52%	5.14%	0.90%	3.61%	5.58%	-234.13%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	4.27	1.33	-1.74	-0.60	0.26	3.39	1.29	2.03	3.75	-149.46
NOPAT to Interest Expense	4.65	0.24	-1.22	-0.42	0.18	4.19	0.43	1.41	2.33	-104.63
EBIT Less CapEx to Interest Expense	2.50	-0.30	-2.89	-1.74	-0.57	1.61	-0.03	0.13	2.81	-151.18
NOPAT Less CapEx to Interest Expense	2.88	-1.40	-2.36	-1.56	-0.65	2.41	-0.89	-0.49	1.39	-106.34
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	124.72%	90.10%	60.99%	-41.94%	-24.01%	-30.91%	-43.57%	363.64%	120.38%	-3.26%

Frequently Asked Questions About Avanos Medical's Financials

When does Avanos Medical's fiscal year end?

According to the most recent income statement we have on file, Avanos Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Avanos Medical's net income changed over the last 2 years?

Avanos Medical's net income appears to be on an upward trend, with a most recent value of -$392.10 million in 2024, falling from $50.50 million in 2022. The previous period was -$61.80 million in 2023. See Avanos Medical's forecast for analyst expectations on what’s next for the company.

What is Avanos Medical's operating income?

Avanos Medical's total operating income in 2024 was -$396.20 million, based on the following breakdown:

Total Gross Profit: $381.30 million
Total Operating Expenses: $777.50 million

How has Avanos Medical revenue changed over the last 2 years?

Over the last 2 years, Avanos Medical's total revenue changed from $684.10 million in 2022 to $687.80 million in 2024, a change of 0.5%.

How much debt does Avanos Medical have?

Avanos Medical's total liabilities were at $325.70 million at the end of 2024, a 28.6% decrease from 2023, and a 34.3% decrease since 2022.

How much cash does Avanos Medical have?

In the past 2 years, Avanos Medical's cash and equivalents has ranged from $87.70 million in 2023 to $127.70 million in 2022, and is currently $107.70 million as of their latest financial filing in 2024.

How has Avanos Medical's book value per share changed over the last 2 years?

Over the last 2 years, Avanos Medical's book value per share changed from 27.77 in 2022 to 18.03 in 2024, a change of -35.1%.

Related Companies

This page (NYSE:AVNS) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avanos Medical (AVNS) Financials

Frequently Asked Questions About Avanos Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avanos Medical (AVNS) Financials

Annual Income Statements for Avanos Medical

Quarterly Income Statements for Avanos Medical

Annual Cash Flow Statements for Avanos Medical

Quarterly Cash Flow Statements for Avanos Medical

Annual Balance Sheets for Avanos Medical

Quarterly Balance Sheets for Avanos Medical

Annual Metrics and Ratios for Avanos Medical

Quarterly Metrics and Ratios for Avanos Medical

Frequently Asked Questions About Avanos Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools